Annals of the Rheumatic Diseases 2017 5.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Downloaded from http://ard.bmj.com/ on April 20, 2017 - Published by group.bmj.com Contents Volume 76 Issue 5 | ARD May 2017 ARDThe Eular Journal May 2017 Volume 76 Issue 5 76 Impact Factor 5 Editorial Clinical and epidemiological research 12.384 Volume 76 Volume Issue 5 779–934 Pages 779 Lesinurad combination therapy with allopurinol 811 Lesinurad in combination with allopurinol: a in gout: do CLEAR studies make the treatment randomised, double-blind, placebo-controlled study of gout clearer? in patients with gout with inadequate response to AnnAls of RheuMAtIc DIseAses of RheuMAtIc AnnAls J A Singh standard of care (the multinational CLEAR 2 study) T Bardin, R T Keenan, P P Khanna, J Kopicko, Criteria M Fung, N Bhakta, S Adler, C Storgard, 782 2016 American College of Rheumatology/ S Baumgartner, A So May 2017 May European League Against Rheumatism Criteria for 821 Development of the autoinflammatory disease Minimal, Moderate, and Major Clinical Response damage index (ADDI) in Juvenile Dermatomyositis: An International N M ter Haar, K V Annink, S M Al-Mayouf, Myositis Assessment and Clinical Studies Group/ G Amaryan, J Anton, K S Barron, S M Benseler, Editor Paediatric Rheumatology International Trials P A Brogan, L Cantarini, M Cattalini, A-V Cochino, Tore K Kvien Organisation Collaborative Initiative F De Benedetti, F Dedeoglu, A A De Jesus, Associate Editors L G Rider, R Aggarwal, A Pistorio, N Bayat, B Erman, O Della Casa Alberighi, E Demirkaya, P Dolezalova, Francis Berenbaum B M Feldman, A M Huber, R Cimaz, R J Cuttica, K L Durrant, G Fabio, R Gallizzi, Johannes Bijlsma R Goldbach-Mansky, E Hachulla, V Hentgen, Dimitrios Boumpas S K de Oliveira, C B Lindsley, C A Pilkington, Gerd Burmester M Punaro, A Ravelli, A M Reed, K Rouster-Stevens, T Herlin, M Hofer, H M Hoffman, A Insalaco, Mary Crow A van Royen-Kerkhof, F Dressler, C Saad Magalhaes, A F Jansson, T Kallinich, I Koné-Paut, A Kozlova, Iain McInnes David Pisetsky T Constantin, J E Davidson, B Magnusson, R Russo, J B Kuemmerle-Deschner, H J Lachmann, R M Laxer, L Villa, M Rinaldi, H Rockette, P A Lachenbruch, A Martini, S Nielsen, I Nikishina, A K Ombrello, Editorial office S Ozen, E Papadopoulou-Alataki, P Quartier, Annals of the Rheumatic Diseases F W Miller, J Vencovsky, N Ruperto, for the BMJ Publishing Group Ltd International Myositis Assessment and Clinical Studies D Rigante, R Russo, A Simon, M Trachana, Y Uziel, BMA House Group and the Paediatric Rheumatology International A Ravelli, M Gattorno, J Frenkel Tavistock Square London WCIH 9JR,UK Trials Organisation T: +44 (0)20 7383 6250 831 A randomised phase II study evaluating F: +44 (0)20 7383 6668 E: [email protected] 792 2016 American College of Rheumatology/European the efficacy and safety of subcutaneously Twitter: @ARD_BMJ League Against Rheumatism criteria for minimal, administered ustekinumab and guselkumab in ISSN: 0003-4967 (print) ISSN: 1468-2060 (online) moderate, and major clinical response in adult patients with active rheumatoid arthritis despite Impact Factor: 12.384 dermatomyositis and polymyositis: An International treatment with methotrexate J S Smolen, S K Agarwal, E Ilivanova, X L Xu, Disclaimer: ARD is owned and published by Myositis Assessment and Clinical Studies Group/ BMJ Publishing Group Ltd (a wholly owned Paediatric Rheumatology International Trials Y Miao, Y Zhuang, I Nnane, W Radziszewski, subsidiary of the British Medical Association) A Greenspan, A Beutler, D Baker and the European League Against Rheumatism. The Organisation Collaborative Initiative owners grant editorial freedom tothe Editor of ARD. ARD follows guidelines on editorial independence R Aggarwal, L G Rider, N Ruperto, N Bayat, produced by the World Association of Medical Editors B Erman, B M Feldman, C V Oddis, A A Amato, 840 Efficacy and safety of sarilumab monotherapy and the code on good publication practice of the Committee on Publication Ethics. H Chinoy, R G Cooper, M Dastmalchi, D Fiorentino, versus adalimumab monotherapy for the ARD is intended for medical professionals and is D Isenberg, J D Katz, A Mammen, M de Visser, treatment of patients with active rheumatoid provided without warranty, express or implied. Statements in the journal are the responsibility S R Ytterberg, I E Lundberg, L Chung, K Danko, arthritis (MONARCH): a randomised, double- of their authors and advertisers and not authors’ I García-De la Torre, Y W Song, L Villa, M Rinaldi, institutions the BMJ Publishing Group, the blind, parallel-group phase III trial European League Against Rheumatism or the H Rockette, P A Lachenbruch, F W Miller, G R Burmester, Y Lin, R Patel, J van Adelsberg, BMA unless otherwise specified or determined J Vencovsky, for the International Myositis Assessment by law. Acceptance of advertising does not imply E K Mangan, N M H Graham, H van Hoogstraten, endorsement. and Clinical Studies Group and the Paediatric D Bauer, J Ignacio Vargas, E B Lee To the fullest extent permitted by law, the BMJ Rheumatology International Trials Organisation Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any Recommendation information they choose to rely on. MORE CONTENTS Copyright: © 2017 BMJ Publishing Group and 802 EULAR/EFORT recommendations for European League Against Rheumatism. All rights management of patients older than 50 years reserved; no part of this publication may be This article has been chosen by the Editor to be of special interest reproduced stored in a retrieval system, or with a fragility fracture and prevention of transmitted in any form or by any means, electronic, or importance and is freely available online. mechanical, photocopying recording, or otherwise subsequent fractures This article has been made freely available online under the BMJ without prior permission W F Lems, K E Dreinhöfer, H Bischoff-Ferrari, ARD is published by BMJ Publishing Group Ltd Journals Open Access scheme. typeset by Exeter Premedia Services Private Ltd, M Blauth, E Czerwinski, JAP da Silva, A Herrera, See http://authors.bmj.com/open-access/ Chennai, India and printed in the UK on acid-free P Hoffmeyer, T Kvien, G Maalouf, D Marsh, paper. Annals of the Rheumatic Diseases (ISSN No: J Puget, W Puhl, G Poor, L Rasch, C Roux, S Schüler, 0003-4967) is published monthly by BMJ Publishing B Seriolo, U Tarantino, T van Geel, A Woolf, Group and distributed in the USA by Air Business Ltd. C Wyers, P Geusens Periodicals postage paid at Jamaica NY 11431 This journal is a member of and subscribes to the principles of the POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Committee on Publication Ethics Shipping Inc., 156-15, 146th Avenue, 2nd Floor, http://publicationethics.org/ Jamaica, NY 11434, USA. Downloaded from http://ard.bmj.com/ on April 20, 2017 - Published by group.bmj.com Contents Volume 76 Issue 5 | ARD May 2017 848 Risk of diabetes mellitus associated with Basic and translational research disease-modifying antirheumatic drugs and 891 Hydroxychloroquine inhibits proinflammatory statins in rheumatoid arthritis signalling pathways by targeting endosomal G Ozen, S Pedro, M E Holmqvist, M Avery, NADPH oxidase F Wolfe, K Michaud N Müller-Calleja, D Manukyan, A Canisius, D Strand, K J Lackner 855 The patient perspective on absence of disease activity in rheumatoid arthritis: a 898 An expanded population of pathogenic regulatory survey to identify key domains of patient- T cells in giant cell arteritis is abrogated by IL-6 perceived remission blockade therapy L H D van Tuyl, M Sadlonova, S Hewlett, B Davis, C Miyabe, Y Miyabe, K Strle, N D Kim, J H Stone, C Flurey, N Goel, L Gossec, C Heegaard Brahe, A D Luster, S Unizony C L Hill, W Hoogland, J Kirwan, M L Hetland, D van Schaardenburg, J S Smolen, T Stamm, 906 Genetic architecture distinguishes systemic M Voshaar, G A Wells, M Boers juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and 862 Cytosolic 5′-nucleotidase 1A autoantibody therapeutic implications profile and clinical characteristics in inclusion M J Ombrello, V L Arthur, E F Remmers, A Hinks, body myositis I Tachmazidou, A A Grom, D Foell, A Martini, J B Lilleker, A Rietveld, S R Pye, K Mariampillai, M Gattorno, S Özen, S Prahalad, A S Zeft, O Benveniste, M T J Peeters, J A L Miller, J F Bohnsack, N T Ilowite, E D Mellins, R Russo, M G Hanna, P M Machado, M J Parton, C Len, M Odete E Hilario, S Oliveira, R S M Yeung, K R Gheorghe, U A Badrising, I E Lundberg, A M Rosenberg, L R Wedderburn, J Anton, J-P Haas, S Sacconi, M K Herbert, N J McHugh, B R F Lecky, A Rosen-Wolff, K Minden, K Tenbrock, E Demirkaya, C Brierley, D Hilton-Jones, J A Lamb, M E Roberts, J Cobb, E Baskin, S Signa, E Shuldiner, R H Duerr, R G Cooper, C G J Saris, G J M Pruijn, H Chinoy, J-P Achkar, M I Kamboh, K M Kaufman, L C Kottyan, B G M van Engelen, On behalf of all D Pinto, S W Scherer, M E Alarcón-Riquelme, UKMYONET contributors E Docampo, X Estivill, A Gül, British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group, 869 GWAS of clinically defined gout and subtypes Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) Study Group, identifies multiple susceptibility loci that include Childhood Arthritis Prospective Study (CAPS) Group, urate transporter genes Randomized Placebo Phase Study of Rilonacept in sJIA A Nakayama, H Nakaoka, K Yamamoto, (RAPPORT) Investigators,